{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:07:19Z","timestamp":1789225639878,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ijantimicag.2022.106574","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T21:49:17Z","timestamp":1647553757000},"page":"106574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study"],"prefix":"10.1016","volume":"59","author":[{"given":"Michaela","family":"Tutone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3490-6460","authenticated-orcid":false,"given":"Truls E.","family":"Bjerklund Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazad","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Livermore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106574_bib0001","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4081\/aiua.2018.2.85","article-title":"Resistance of uropathogens to antibacterial agents: emerging threats, trends and treatments","volume":"90","author":"Perletti","year":"2018","journal-title":"Arch Ital Urol Androl"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0002","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0003","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ajog.2017.12.231","article-title":"Diagnosis and treatment of urinary tract infections across age groups","volume":"219","author":"Chu","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0004","first-page":"361","article-title":"The diagnosis of urinary tract infection: a systematic review","volume":"107","author":"Schmiemann","year":"2010","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0005","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMcp1104429","article-title":"Uncomplicated urinary tract infection","volume":"366","author":"Hooton","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0006","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/cid\/ciw396","article-title":"Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens","volume":"63","author":"Walker","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0007","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4103\/UA.UA_104_19","article-title":"Management of urinary tract infection in women: a practical approach for everyday practice","volume":"11","author":"Abou Heidar","year":"2019","journal-title":"Urol Ann"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/1756287219832174","article-title":"Appropriate use of antibiotics: an unmet need","volume":"11","author":"Lopez Romo","year":"2019","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105966","article-title":"Office-based approach to urinary tract infections in 50 000 patients: results from the REWIND study","volume":"56","author":"Cai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/jac\/dkl483","article-title":"CTX-M: changing the face of ESBLs in Europe","volume":"59","author":"Livermore","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0011","doi-asserted-by":"crossref","first-page":"e01911","DOI":"10.1128\/AAC.01911-16","article-title":"Inventory of extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae in France as assessed by a multicenter study","volume":"61","author":"Robin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0012","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1179\/1973947813Y.0000000121","article-title":"Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009\u20132011)","volume":"26","author":"Sader","year":"2014","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0013","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9519718","article-title":"The growing genetic and functional diversity of extended spectrum \u03b2-lactamases","volume":"2018","author":"ur Rahman","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7656752","article-title":"Community-acquired urinary tract infection by Escherichia coli in the era of antibiotic resistance","volume":"2018","author":"Lee","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0015","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/QCO.0b013e328358afe5","article-title":"\u2018Old\u2019 antibiotics for emerging multidrug-resistant bacteria","volume":"25","author":"Bergen","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0016","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/JU.0000000000000620","article-title":"Fosfomycin trometamol versus comparator antibiotics for the treatment of acute uncomplicated urinary tract infections in women: a systematic review and meta-analysis","volume":"203","author":"Cai","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0017","series-title":"EUCAST general consultation on fosfomycin oral (trometamol) breakpoints for Enterobacterales","year":"2020"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0018","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 2021. http:\/\/www.eucast.org [accessed 18 March 2022]."},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0019","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2019"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0020","doi-asserted-by":"crossref","first-page":"e85889","DOI":"10.1371\/journal.pone.0085889","article-title":"High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli","volume":"9","author":"Soraas","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/mdr.2011.0161","article-title":"Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"18","author":"Titelman","year":"2012","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0022","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","article-title":"Epidemiology, definition and treatment of complicated urinary tract infections","volume":"17","author":"Wagenlehner","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0023","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jhin.2016.12.008","article-title":"Epidemiology of Escherichia coli bacteraemia in England: results of an enhanced sentinel surveillance programme","volume":"95","author":"Abernethy","year":"2017","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0024","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/jgid.jgid_86_17","article-title":"Community-acquired lower urinary tract infections: etiology, antimicrobial resistance, and treatment results in female patients","volume":"10","author":"Erdem","year":"2018","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0025","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0026","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3947\/ic.2018.50.1.67","article-title":"Clinical practice guidelines for the antibiotic treatment of community-acquired urinary tract infections","volume":"50","author":"Kang","year":"2018","journal-title":"Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0027","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/AOG.0b013e318169f6ef","article-title":"American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 91: Treatment of urinary tract infections in nonpregnant women","volume":"111","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0028","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1086\/322603","article-title":"Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis","volume":"33","author":"Le","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0029","first-page":"35","article-title":"Escherichia coli resistance in uncomplicated urinary tract infection: a model for determining when to change first-line empirical antibiotic choice","volume":"15","author":"Perfetto","year":"2002","journal-title":"Manag Care Interface"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0030","series-title":"Quinolone- and fluoroquinolone-containing medicinal products","year":"2018"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0031","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1089\/mdr.2019.0467","article-title":"The global prevalence of class 1 integron and associated antibiotic resistance in Escherichia coli from patients with urinary tract infections, a systematic review and meta-analysis","volume":"26","author":"Halaji","year":"2020","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0032","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dky453","article-title":"OXA-1 \u03b2-lactamase and non-susceptibility to penicillin\/\u03b2-lactamase inhibitor combinations among ESBL-producing Escherichia coli","volume":"74","author":"Livermore","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0033","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1128\/CMR.00125-13","article-title":"Escherichia coli ST131, an intriguing clonal group","volume":"27","author":"Nicolas-Chanoine","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0034","unstructured":"European Centre for Disease Prevention and Control (ECDC). European Antimicrobial Resistance Surveillance Network (EARS-Net).https:\/\/www.ecdc.europa.eu\/en\/about-us\/partnerships-and-networks\/disease-and-laboratory-networks\/ears-net [accessed 18 March 2022 ]."},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0035","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/jac\/dkl368","article-title":"Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care","volume":"58","author":"McNulty","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0036","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ijantimicag.2019.06.015","article-title":"Comparison of antibiotic treatment guidelines for urinary tract infections in 15 European countries: results of an online survey","volume":"54","author":"Malmros","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0037","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. http:\/\/www.eucast.org\/clinical_breakpoints\/ [accessed 18 March 2022]."},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0038","series-title":"MIC and inhibition zone diameter distributions of microorganisms without and with phenotypically evident resistance mechanisms","year":"2021"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0039","series-title":"EAU guidelines on urological infections","author":"Bonkat","year":"2022"},{"key":"10.1016\/j.ijantimicag.2022.106574_bib0040","series-title":"EAU guidelines on urological infections","first-page":"22","author":"Bonkat","year":"2017"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922000747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922000747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:44:12Z","timestamp":1760377452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922000747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0924857922000747"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106574","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106574"}}